Skip to content

Blog

Category: Immunogenicity

<a href="https://www.bioagilytix.com/blog/category/immunogenicity/">Immunogenicity</a>

Immunogenicity Testing For Biosimilars

  • December 19, 2022

Entering the biosimilars market is an enticing prospect for many biopharma companies, offering the potential for reduced development and manufacturing costs while providing patients with…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/car-t-cell-therapy/">CAR-T Cell Therapy</a>

Determining Immunogenicity for CAR-T cell Therapies

  • September 27, 2022

Chimeric Antigen Receptor (CAR)-T cell therapy is a novel cancer therapy that harnesses and redirects the cytotoxic activity of T cells against cancer cells. CAR-T…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/gene-therapy/">Gene Therapy</a>

Challenges for Measuring Immunogenicity of AAV-based Gene Therapies

  • September 15, 2021

Gene therapy is a powerful form of treatment that involves introducing genetic material into cells to replace defective genes resulting in the production of an…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/gene-therapy/">Gene Therapy</a>

Impact of Pre-Existing Immunogenicity Against AAV on Gene Therapy Trials

  • July 23, 2020

The concept of using pre-existing immunogenicity as an exclusion criteria for gene therapy clinical trials is changing. BioAgilytix’s Chief Scientific Officer, Dr. Jim McNally, explores…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/cro-selection/">CRO Selection</a>

Turning Around a Troubled Study: A Rescue Project Success Story

  • April 13, 2020

When you have a program that has stalled or gone off schedule, it is vital to team up with a CRO laboratory that is capable…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/immunogenicity/">Immunogenicity</a>

Webinar Sneak Peek: Accelerating Testing of Therapeutics to Neutralize Viral Infections

  • April 7, 2020

On May 7, we'll be hosting webinar highlighting the importance of streamlining the time & cost of bioanalytical testing to support therapeutic development for viral…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Answers to Your Questions on Immunogenicity Testing for Biosimilars: Part 2

  • February 26, 2020

BioAgilytix’s Todd Lester answers additional questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioagilytix-insight/">BioAgilytix Insight</a>

Questions on Immunogenicity Testing for Biosimilars Answered: Part 1

  • February 18, 2020

BioAgilytix’s Todd Lester answers questions submitted by attendees of his recent Bioanalysis Zone webinar on immunogenicity testing for biosimilars.

Find Out More
<a href="https://www.bioagilytix.com/blog/category/bioanalytical-platforms/">Bioanalytical Platforms</a>

Platform Spotlight: ImmunoCAP to Support Diagnosis of Allergic Reactions Against Biologics

  • July 25, 2019

The observation of drug-specific IgE antibodies which may cause anaphylaxis prompts the need to test for these antibodies - but because IgE are 2000-fold less…

Find Out More
<a href="https://www.bioagilytix.com/blog/category/immunogenicity/">Immunogenicity</a>

Immunogenicity Assessment Using the Biacore™ T200 SPR System

  • July 18, 2019

What are the advantages of using the Biacore™ T200 SPR System for immunogenicity assessments with a tiered approach? Our experts discuss.

Find Out More